A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma



Status:Recruiting
Conditions:Asthma
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:4 - Any
Updated:3/23/2019
Start Date:December 27, 2018
End Date:December 1, 2020
Contact:Piotr Bernat, PharmD
Email:piotr.bernat@syneoshealth.com
Phone:48 22 219 5184

Use our guide to learn which trials are right for you!

A Long-term, Randomized, Double-blind, Multicenter, Parallel-group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT007 Administered as Needed in Response to Symptoms in Symptomatic Adults and Children 4 Years of Age or Older With Asthma

This is a randomized, double-blind, multicenter, parallel-group, variable-length study to
compare 2 doses of BDA MDI (PT027) with AS MDI (PT007) on the time to first severe asthma
exacerbation in adult, adolescent, and pediatric subjects with moderate to severe asthma.


Inclusion Criteria:

1. Female or male aged ≥4 years at the time of informed consent

2. Physician diagnosis of asthma documented for at least 1 year

3. Receiving 1 of the following scheduled asthma maintenance therapies for 3 months with
stable dosing for at least the last 4 weeks before Visit 1:

- Medium-to-high-dose inhaled corticosteroid (ICS)

- Medium-to-high-dose ICS and 1 additional maintenance therapy from the following:
leukotriene receptor antagonists (LTRA), long-acting muscarinic antagonists
(LAMA), or theophylline

- Low-to-high-dose ICS in combination with long-acting β2-adrenoreceptor agonist
(LABA) with or without one additional maintenance therapy from the following:
LTRA, LAMA, or theophylline

4. Prebronchodilator forced expiratory volume in 1 second (FEV1) of ≥40 to <90% predicted
normal value for adults and adolescents, and ≥60 to <100% predicted normal value for
subjects aged 4 to 11 years after withholding specified medications including
short/rapid-acting β2-adrenoreceptor agonist (SABA)

5. Demonstrate reversibility at Visit 1, with an increase in FEV1 ≥12% (and ≥200 mL for
subjects aged ≥18 years) relative to baseline after administration of sponsor provided
Ventolin via central spirometry. One re-test for reversibility testing is allowed
within the screening period in advance of Visit 2

6. Demonstrate acceptable spirometry performance (i.e., meet American Thoracic
Society/European Respiratory Society acceptability/repeatability criteria)

7. A documented history of at least 1 severe asthma exacerbation within 12 months before
Visit 1

8. Able to perform acceptable and reproducible peak expiratory flow (PEF) measurements as
assessed by the investigator

Exclusion Criteria:

1. Chronic obstructive pulmonary disease or other significant lung disease (e.g., chronic
bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis, or
bronchopulmonary dysplasia)

2. Oral corticosteroid/SCS use (any dose and any indication) within 6 weeks before Visit
1

3. Chronic use of oral corticosteroids (OCS, ≥3 weeks use in 3 months prior to Visit 1)

4. Having received any marketed (e.g., omalizumab, mepolizumab, reslizumab, benralizumab)
or investigational biologic within 3 months or any other prohibited medication

5. Current smokers, former smokers with >10 pack-years history, or former smokers who
stopped smoking <6 months before Visit 1 (including all forms of tobacco, e-cigarettes
[vaping], and marijuana)

6. Life-threatening asthma defined as any history of significant asthma episode(s)
requiring intubation associated with hypercapnia, respiratory arrest, hypoxic
seizures, or asthma related syncopal episode(s) within 5 years of Visit 1

7. Historical or current evidence of a clinically significant disease

8. Cancer not in complete remission for at least 5 years

9. Hospitalization for psychiatric disorder or attempted suicide within 1 year of Visit 1

10. History of psychiatric disease, intellectual deficiency, poor motivation, or other
conditions if their magnitude is limiting informed consent validity

11. Significant abuse of alcohol or drugs
We found this trial at
10
sites
?
mi
from
Ypsilanti, MI
Click here to add this to my saved trials
?
mi
from
Hialeah, FL
Click here to add this to my saved trials
?
mi
from
High Point, NC
Click here to add this to my saved trials
?
mi
from
Medford, OR
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
North Dartmouth, Massachusetts 02747
?
mi
from
North Dartmouth, MA
Click here to add this to my saved trials
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
?
mi
from
Orlando, FL
Click here to add this to my saved trials
?
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
?
mi
from
Warwick, RI
Click here to add this to my saved trials